What Is Aclaris Therapeutics, Inc. (ACRS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Aclaris Therapeutics, Inc.'s intrinsic value is estimated at $1.44, suggesting the stock is overvalued at its current price of $5.50. With 10 out of 11 models flagging downside (-73.8% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $5.44 (-1.2%), while ML-RIV — the most conservative — estimates $0.07 (-98.7%). This +97.5% gap reflects genuine analytical uncertainty about Aclaris Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About ACRS?
11 of 13 models are currently active for ACRS. All 11 active models suggest the stock trades above fair value. The Bayesian DCF estimates ACRS's intrinsic value at $1.79, implying -67.4% downside from the current price. See which stocks rank higher →
How Does ACRS Rank in Biotechnology?
Among 62 Biotechnology stocks, ACRS ranks #4 by Quality of Company score. CirclFi's QOC score of 7.4/10 evaluates 32 fundamental signals. A score of 7.4 indicates above-average quality.
See all Most Undervalued Biotechnology Stocks →
As a biotech sector, Aclaris Therapeutics, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating ACRS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ACRS a Value Trap?
CirclFi's Value Trap algorithm assigns ACRS a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Aclaris Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Aclaris Therapeutics, Inc.'s fundamental quality profile registers 7.4/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +97.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ACRS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ACRS's 11 active models, average confidence is 19%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad